# Faslodex Registry: Fulvestrant in Current Clinical Practice

> **NCT00735215** · — · COMPLETED · sponsor: **AstraZeneca** · enrollment: 200 (estimated)

## Conditions studied

- Metastatic Breast Cancer

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT00735215
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2008-10
- **Primary completion:** —
- **Final completion:** 2009-12
- **Target enrollment:** 200 (ESTIMATED)
- **Last updated:** 2009-12-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00735215

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00735215, "Faslodex Registry: Fulvestrant in Current Clinical Practice". Retrieved via AI Analytics 2026-08-21 from https://api.ai-analytics.org/clinical/NCT00735215. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*